Simplest, Shortest Administration Time for

A FIRST-LINE COMBINATION REGIMEN FOR *EGFR*+ NSCLC

THE CHALLENGE: A DISEASE THAT RESISTS TREATMENT

About every 2 minutes, someone in the US is diagnosed with lung cancer, and globally, lung cancer remains the leading cause of cancer death worldwide.[1,2] Non–small cell lung cancer (NSCLC) accounts for **approximately 85% of all lung cancer cases.**[2]

Many NSCLC cases are driven by epidermal growth factor receptor (*EGFR*) mutations, often found in younger, non-smoking individuals, which promote uncontrolled cell growth and are linked to poor health outcomes.[4] Historically, **fewer than 20% of people with *EGFR*-mutated NSCLC live beyond 5 years.**[5]

The resistance challenge: Even when treatments initially work, cancer cells can adapt and continue growing. Overcoming these resistance mechanisms—such as *MET* amplification and secondary *EGFR* mutations—is essential for improving outcomes and extending survival in *EGFR*-mutated NSCLC.[6]

INTRODUCING RYBREVANT *FASPRO*™: A NEW SUBCUTANEOUS TREATMENT

RYBREVANT *FASPRO*™ (AMIVANTAMAB AND HYALURONIDASE-LPUJ) IS APPROVED FOR ALL INDICATIONS OF RYBREVANT®.

US FDA approval of RYBREVANT *FASPRO*™, **the first and only subcutaneous therapy for adult patients with *EGFR*-mutated advanced or metastatic NSCLC,** enables a simpler and shorter administration time for a first-line combination regimen compared to intravenous-based regimens.[7-13]

RYBREVANT® is approved in the US across 4 indications in *EGFR*-mutated NSCLC, including 2 in the first-line setting and 2 in the second-line setting, for patients with either exon 19 deletions, exon 21 L858R mutations, or exon 20 insertion mutations, as monotherapy or in combination with LAZCLUZE® (lazertinib) or chemotherapy.[7]

RYBREVANT *FASPRO*™, RYBREVANT®, and LAZCLUZE® may cause serious side effects, including allergic and injection-related reactions, infusion-related reactions, lung problems, blood clot problems, skin problems, and eye problems.

Please see **Important Safety Information on the right.**

HOW IT WORKS: TARGETING *EGFR*+ NSCLC WITH SUBCUTANEOUS DELIVERY

A CHEMOTHERAPY-FREE COMBINATION TREATMENT DESIGNED TO ADDRESS RESISTANCE

RYBREVANT® plus LAZCLUZE® works through a multitargeted mode of action: it blocks and degrades *EGFR* and *MET* receptors, and activates the immune system.[11] In a clinical study, this chemotherapy-free regimen has demonstrated significant progression-free survival and overall survival benefit vs osimertinib in the first-line setting, while reducing the development of resistance mechanisms.[6,13,14]

RYBREVANT *FASPRO*™ delivers **consistent results** compared to intravenous (IV) RYBREVANT®, while offering:

SHORTER ADMINISTRATION TIME

- From several hours to approximately 5 minutes
  - *Administration time only, actual clinic time may vary*

FEWER ADMINISTRATION-RELATED REACTIONS

- Fivefold reduction compared to IV delivery

REDUCED RISK OF BLOOD CLOTS

- Lower incidence of venous thromboembolism (VTE) compared to IV administration with anticoagulant use

CONSISTENT PHARMACOKINETIC PROFILE

- Similar amivantamab exposure for subcutaneous compared to IV delivery

Subcutaneous administration can reduce treatment time and ease the burden on patients and healthcare resources associated with lengthy infusions.[8,15]

LEARN MORE

Visit www.RYBREVANT.com to learn more about RYBREVANT *FASPRO*™ and the clinical trials supporting this approval.
Talk to your healthcare provider today.

RYBREVANT Faspro® (amivantamab and hyaluronidase-lpuj)
LAZCLUZE® (lazertinib)

What should I avoid while receiving RYBREVANT *FASPRO*™, RYBREVANT®, and/or LAZCLUZE®?

RYBREVANT *FASPRO*™, RYBREVANT®, and LAZCLUZE® can cause skin reactions. You should limit your time in the sun during and for 2 months after your treatment. Wear protective clothing and use broad-spectrum sunscreen during treatment.

What are the possible side effects of RYBREVANT *FASPRO*™, RYBREVANT®, or LAZCLUZE®?

RYBREVANT *FASPRO*™, RYBREVANT®, and LAZCLUZE® may cause serious side effects, including:

- **allergic and injection-related reactions.** Allergic and injection-related reactions are common with RYBREVANT *FASPRO*™ and can be severe or serious. Tell your HCP right away if you get any of the following symptoms during or after your injection: shortness of breath, fever, chills, flushing, chest discomfort, dizziness or lightheadedness, or vomiting.
- **infusion-related reactions.** Infusion-related reactions are common with RYBREVANT® but can be severe or serious and can include life-threatening (anaphylaxis) allergic reaction. Tell your HCP right away if you get any of the following symptoms during your infusion of RYBREVANT®: shortness of breath, difficulty breathing, or wheezing, chest discomfort, swelling of your eyes, lips, or tongue, fever, chills, numbness of your tongue, lips, cheeks, or gums, flushing, skin rash, hives, or itching, nausea or vomiting, stomach cramps, lightheadedness, dizziness, or fainting, or headache.
- **lung problems.** RYBREVANT *FASPRO*™, RYBREVANT®, or LAZCLUZE® can cause lung problems that can lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your HCP right away if you get any new or worsening lung symptoms, including shortness of breath, cough, or fever.
- **blood clot problems.** RYBREVANT *FASPRO*™ or RYBREVANT®, when given in combination with LAZCLUZE®, can cause blood clots in the veins of your legs (deep vein thrombosis) or lungs (pulmonary embolism) that can lead to death. Your HCP may start you on medicine to prevent blood clots for the first 4 months of treatment. Tell your HCP right away if you get any signs and symptoms of blood clots, including swelling, pain or tenderness in the leg, sudden unexplained chest pain, or shortness of breath.
- **skin problems.** RYBREVANT *FASPRO*™, RYBREVANT®, or LAZCLUZE® can cause severe rash, including blisters, peeling, skin pain and sores, redness, raised acne-like bumps, itching, and dry skin. Your HCP may start you on an antibiotic for the first 3 months of treatment followed by an antibiotic lotion for your scalp for the next 9 months. During treatment, you should apply a non-comedogenic (does not clog pores) skin moisturizer (ceramide-based or other types of moisturizers that provide long lasting skin hydration and does not include drying ingredients) on your face and whole body (except scalp) and wash your hands well every day with 4% chlorhexidine solution. Tell your HCP right away if you get any skin reactions. Your HCP may treat you with a medicine(s) or send you to see a skin specialist (dermatologist) if you get skin reactions during treatment.
- **eye problems.** RYBREVANT *FASPRO*™, RYBREVANT®, and LAZCLUZE® can cause eye problems. Tell your HCP right away if you get symptoms of eye problems including eye pain, inflammation of eyelids, dry eyes, eye redness, blurred vision, changes in vision, itchy eyes, excessive tearing, and sensitivity to light. Your HCP may send you to see an eye specialist (ophthalmologist) if you get new or worsening eye problems during treatment with RYBREVANT *FASPRO*™, RYBREVANT®, or LAZCLUZE®. You should not use contact lenses until your eye symptoms are checked by an HCP.

The most common side effects of RYBREVANT *FASPRO*™ in combination with LAZCLUZE® include: rash, infected skin around the nail, muscle and joint pain, feeling very tired, sores in the mouth, swelling of hands, ankles, feet, face, or all of your body, nausea, diarrhea, vomiting, constipation, decreased appetite, headache, and changes in certain blood tests.

The most common side effects seen with intravenous (IV) RYBREVANT®, which may be experienced with RYBREVANT *FASPRO*™, are listed below.

- **RYBREVANT® in combination with LAZCLUZE®:** rash, infected skin around the nail, infusion-related reaction, muscle and joint pain, sores in the mouth, swelling of hands, ankles, feet, face, or all of your body, unusual feeling in the skin (such as tingling or a crawling feeling), feeling very tired, diarrhea, constipation, COVID-19, bleeding, dry skin, decreased appetite, itchy skin, nausea, and changes in certain blood tests.
- **RYBREVANT® in combination with carboplatin and pemetrexed:** rash, infected skin around the nail, infusion-related reaction, feeling very tired, nausea, sores in the mouth, constipation, swelling of hands, ankles, feet, face, or all of your body, decreased appetite, muscle and joint pain, vomiting, COVID-19, and changes in certain blood tests.
- **RYBREVANT® given alone:** rash, infusion-related reaction, infected skin around the nail, muscle and joint pain, shortness of breath, nausea, swelling of hands, ankles, feet, face, or all of your body, cough, feeling very tired, sores in the mouth, constipation, vomiting, and changes in certain blood tests.

LAZCLUZE® may cause fertility problems in males and females, which may affect your ability to have children. Talk to your HCP if this is a concern for you.

Your HCP may temporarily stop, decrease your dose, or completely stop your treatment with RYBREVANT *FASPRO*™, RYBREVANT®, or LAZCLUZE® if you have serious side effects.

These are not all of the possible side effects of RYBREVANT *FASPRO*™, RYBREVANT®, or LAZCLUZE®.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of RYBREVANT *FASPRO*™, RYBREVANT®, or LAZCLUZE®:

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet.

You can ask your HCP or pharmacist for information about RYBREVANT *FASPRO*™, RYBREVANT®, or LAZCLUZE® that is written for health professionals. Do not use LAZCLUZE® for a condition for which it was not prescribed. Do not give LAZCLUZE® to other people, even if they have the same symptoms that you have. It may harm them.

What are RYBREVANT *FASPRO*™ (amivantamab and hyaluronidase-lpuj) and RYBREVANT® (amivantamab-vmjw)?

RYBREVANT *FASPRO*™ and RYBREVANT® are prescription medicines used to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and has certain abnormal epidermal growth factor receptor (EGFR) gene(s):

- in combination with LAZCLUZE® (lazertinib), a prescription medicine, as a first-line treatment for NSCLC
- in combination with carboplatin and pemetrexed for NSCLC in people whose disease has worsened on or after treatment with an EGFR tyrosine kinase inhibitor (TKI)
- in combination with carboplatin and pemetrexed as a first-line treatment for NSCLC
- alone for the treatment of NSCLC in people whose disease has worsened on or after platinum-based chemotherapy.

Your healthcare provider will perform a test to make sure that RYBREVANT *FASPRO*™ or RYBREVANT® is right for you.

It is not known if RYBREVANT *FASPRO*™, RYBREVANT®, or LAZCLUZE® are safe and effective in children.

IMPORTANT SAFETY INFORMATION

Do not take RYBREVANT *FASPRO*™ if you are allergic to hyaluronidase or any of the ingredients in RYBREVANT *FASPRO*™.

Before you receive RYBREVANT *FASPRO*™, RYBREVANT® or LAZCLUZE®, tell your healthcare provider (HCP) about all of your medical conditions, including if you:

- have a history of lung or breathing problems, other than cancer.
- are pregnant or plan to become pregnant. RYBREVANT *FASPRO*™, RYBREVANT® and LAZCLUZE® can harm your unborn baby.

  Females who are able to become pregnant:
  - Your HCP should do a pregnancy test before you start treatment with RYBREVANT *FASPRO*™, RYBREVANT®, or LAZCLUZE®.
  - If you are taking RYBREVANT *FASPRO*™ or RYBREVANT®, use effective birth control (contraception) during treatment and for 3 months after your last dose. If you are taking LAZCLUZE®, use effective birth control (contraception) during treatment and for 3 weeks after your last dose.
  - Tell your HCP right away if you become pregnant or think you might be pregnant during treatment with RYBREVANT *FASPRO*™, RYBREVANT®, or LAZCLUZE®.

  Males who have female partners who are able to become pregnant:
  - You should use effective birth control during treatment and for 3 weeks after your last dose of LAZCLUZE®.
- are breastfeeding or plan to breastfeed. It is not known if RYBREVANT *FASPRO*™, RYBREVANT®, or LAZCLUZE® pass into your breast milk. Do not breastfeed during treatment and for 3 months after your last dose of RYBREVANT *FASPRO*™ or RYBREVANT®. Do not breastfeed during treatment and for 3 weeks after your last dose of LAZCLUZE®.

Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. LAZCLUZE® may affect the way other medicines work, and other medicines may affect how LAZCLUZE® works. You should not start or stop any medicine before you talk with your HCP that prescribed LAZCLUZE®.

Please read full Prescribing Information for **RYBREVANT *FASPRO*™**, **RYBREVANT®**, and **LAZCLUZE®**.

cp-493867v1

REFERENCES

1. American Lung Association. State of lung cancer – key findings. Accessed November 2025. https://www.lung.org/research/state-of-lung-cancer/key-findings
2. World Health Organization. Cancer Today – Globocan 2022. Accessed November 2025. https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdf
3. American Cancer Society. What is lung cancer? Accessed July 2025. https://www.cancer.org/content/cancer/en/cancer/lung-cancer/about/what-is.html
4. American Cancer Society. Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management. Accessed November 2025. https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.70024
5. Lin JJ, Cardarella S, Lydon CA, et al. Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs. *J Thorac Oncol*. 2016;11(4):556-565. doi:10.1016/j.jtho.2015.12.103
6. Hayashi H, Besse B, Lee S-H, et al. Mechanisms of acquired resistance to first-line amivantamab plus lazertinib vs osimertinib: updated analysis from MARIPOSA [ASLC abstract PT1 03]. Presented at: IASLC 2025 World Lung Conference on Lung Cancer; September 6-9, 2025; Barcelona, Spain.
7. RYBREVANT® [Prescribing Information]. Horsham, PA. Janssen Biotech, Inc.
8. George S, Bourlon MT, Overman MJ, et al. Systematic literature review of intravenous versus subcutaneous administration of oncology therapies: a clinical, economic and patient perspective. *Cancer Treat Rev*. 2025;139:102974. doi:10.1016/j.ctrv.2025.102974
9. Bittner B, Richter W, Schmidt J. Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. *BioDrugs*. 2018;32(5):425-440. doi:10.1007/s40259-018-0295-0
10. Aguiar-Ibáñez R, Fotheringham I, Mittal L, et al. Differences between intravenous and subcutaneous modes of administration in oncology from the patient, healthcare provider, and healthcare system perspectives: a systematic review. *Adv Ther*. 2024;41(12):4396-4417. doi:10.1007/s12325-024-02985-9
11. Epstein RS, Krenitsky J, Theuer CP, et al. Cancer patients' perspectives: a qualitative study of reasons for subcutaneous preference vs intravenous treatment. *J Clin Oncol*. 2025;43(16_suppl). doi:10.1200/jco.2025.43.16_suppl.e23124
12. Parra A, Hernández C, Prieto-Pinto L. Evaluation of the economic benefits, administration times, and patient preferences associated with the use of biotechnological drugs administered subcutaneously and intravenously in patients with cancer: a systematic review. *Expert Rev Pharmacoecon Outcomes Res*. 2023;23(10):1017-1026. doi:10.1080/14737167.2023.2249232
13. Alexander M, Cheng Y, Lee SH, et al. Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: patient satisfaction and resource utilization results from the PALOMA-3 study. *Eur J Cancer*. 2025;227:115624. doi:10.1016/j.ejca.2025.115624
14. RYBREVANT® [Prescribing Information]. Horsham, PA. Janssen Biotech, Inc.
15. Cho BC, Lu S, Felip E, et al; MARIPOSA Investigators. Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC. *N Engl J Med*. 2024;391(16):1486-1498. doi:10.1056/NEJMoa2403614
16. Yang JC, Lu S, Hayashi H, et al. Overall survival with amivantamab–lazertinib in EGFR-mutated advanced NSCLC. *N Engl J Med*. 2025;393(13):1681-1693. doi:10.1056/NEJMoa2503001